Interclean Shanghai

New Study Discovers Near-Infrared Light Therapy (NILT) Effectively Treats Traumatic Brain Injury

A new study published today in the journal, Neuropsychiatric Disease and Treatment, is being hailed as a "medical breakthrough" in the treatment of traumatic brain injury (TBI), which plagues millions of athletes, military veterans and first-responder professionals.

Photo – http://photos.prnewswire.com/prnh/20150821/260217

The study, "Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy," found that a specific high-powered, near infrared light (NIR) can effectively re-energize damaged brain cells after penetrating the skin and skull. All the patients in the study reported significant clinical improvement in their condition with no negative side effects, according to Theodore Henderson, MD, PhD, who co-authored the study along with Dr. Larry Morries, and Paolo Cassano of Massachusetts General. This is the second largest study of NIR for brain injury and the only one using the more powerful Class-IV laser to deliver NIR, Dr. Henderson said.

"This is a real game changer," said Dr. Henderson, co-founder of the Neuro-Laser Foundation, "because these patients have retained the benefits for up to four years now. For those who have been told there is no treatment for TBI, we invite you to look closely at what we've found and you will regain hope."

The Centers for Disease Control report over 2.5 million emergency visits for concussions and TBI annually, said Dr. Henderson. Athletes with multiple sub-concussive blows and military veterans with TBI (over 307,000) also have lasting symptoms. These symptoms can include headaches, speech irregularities, confusion, memory slips, lack of impulse control, sleep disturbance, anxiety, depression, and for some, suicide.
"Patients from the study experienced a significant reduction of their depressive symptoms as demonstrated using standardized depression scales," Dr. Henderson said. "They all improved dramatically. Headaches, depression, anxiety, insomnia, irritability, mood swings, sleep problems, and relationship problems all resolved. Several unemployed patients returned to work or started new careers."
The study occurred from 2011-2013 with 10 people diagnosed with chronic mild-to-moderate TBI as a result of involvement in athletics, military activities or as first-responders. The treatments included 10 transcranial applications of high-power NIR over the course of two months. Using a Class IV laser and pulsed light, each treatment took less than 60 minutes. Previous studies with low-powered NIR had shown on transient benefits. In this study, Morries and colleagues report benefits lasting for years after treatment.
The exciting news is that NIR light, in the 10-15W range at 810 nm and 980 nm, can safely and effectively treat chronic symptoms of TBI, Dr. Henderson said. However, he cautions that low-powered NIR or diode-based infrared light does not even penetrate the skin, so not every type of NIR treatment would be as effective as what Dr. Morries and colleagues have published here.
"We have seen the effectiveness of NILT transform people's lives. Now, we plan on making this treatment more widely available," said Dr. Henderson.
The Neuro-Laser Foundation (NLF) is a non-profit organization based in Denver, Colorado, dedicated to advancing technology and treatment that will increase quality of life for people impacted by traumatic brain injury and other complex psychiatric conditions.

A new study published today in the journal, Neuropsychiatric Disease and Treatment, is being hailed

A new study published today in the journal, Neuropsychiatric Disease and Treatment, is being hailed as a "medical breakthrough" in the treatment of traumatic brain injury (TBI), which plagues millions of athletes, military veterans and first-responder professionals.

Photo – http://photos.prnewswire.com/prnh/20150821/260217

The study, "Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy," found that a specific high-powered, near infrared light (NIR) can effectively re-energize damaged brain cells after penetrating the skin and skull. All the patients in the study reported significant clinical improvement in their condition with no negative side effects, according to Theodore Henderson, MD, PhD, who co-authored the study along with Dr. Larry Morries, and Paolo Cassano of Massachusetts General. This is the second largest study of NIR for brain injury and the only one using the more powerful Class-IV laser to deliver NIR, Dr. Henderson said.

"This is a real game changer," said Dr. Henderson, co-founder of the Neuro-Laser Foundation, "because these patients have retained the benefits for up to four years now. For those who have been told there is no treatment for TBI, we invite you to look closely at what we've found and you will regain hope."

The Centers for Disease Control report over 2.5 million emergency visits for concussions and TBI annually, said Dr. Henderson. Athletes with multiple sub-concussive blows and military veterans with TBI (over 307,000) also have lasting symptoms. These symptoms can include headaches, speech irregularities, confusion, memory slips, lack of impulse control, sleep disturbance, anxiety, depression, and for some, suicide.

"Patients from the study experienced a significant reduction of their depressive symptoms as demonstrated using standardized depression scales," Dr. Henderson said. "They all improved dramatically. Headaches, depression, anxiety, insomnia, irritability, mood swings, sleep problems, and relationship problems all resolved. Several unemployed patients returned to work or started new careers."

The study occurred from 2011-2013 with 10 people diagnosed with chronic mild-to-moderate TBI as a result of involvement in athletics, military activities or as first-responders. The treatments included 10 transcranial applications of high-power NIR over the course of two months. Using a Class IV laser and pulsed light, each treatment took less than 60 minutes. Previous studies with low-powered NIR had shown on transient benefits. In this study, Morries and colleagues report benefits lasting for years after treatment.

The exciting news is that NIR light, in the 10-15W range at 810 nm and 980 nm, can safely and effectively treat chronic symptoms of TBI, Dr. Henderson said. However, he cautions that low-powered NIR or diode-based infrared light does not even penetrate the skin, so not every type of NIR treatment would be as effective as what Dr. Morries and colleagues have published here.

"We have seen the effectiveness of NILT transform people's lives. Now, we plan on making this treatment more widely available," said Dr. Henderson.

The Neuro-Laser Foundation (NLF) is a non-profit organization based in Denver, Colorado, dedicated to advancing technology and treatment that will increase quality of life for people impacted by traumatic brain injury and other complex psychiatric conditions.

$25 million gift creates new UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth

The University of Texas System Board of Regents has approved establishment of the UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth, made possible by an extraordinary $25 million commitment from W.A. "Tex" Moncrief Jr. The Center is UT Southwestern's first named campus outside of Dallas.

The new campus in the heart of Fort Worth's burgeoning medical district will build on UT Southwestern Medical Center's recent expansions at the Moncrief Cancer Institute. It also strengthens the Medical Center's capacity to serve residents of Fort Worth and surrounding areas, improving access to UT Southwestern's medical care, research, and educational opportunities.

"The UT Southwestern Monty and Tex Moncrief Medical Center recognizes the long-standing support and vision of the Moncrief family, which has enabled our growing clinical presence in Fort Worth," said Dr. Daniel K. Podolsky, President of UT Southwestern. "In the years ahead, their remarkable generosity will support the development of a multidisciplinary outpatient facility programmed specifically to meet the medical needs of the area. We are delighted and privileged to be a part of the growing Fort Worth community."

The first building on the 6.3-acre site, located at the intersection of Pennsylvania Avenue and Main Street, is expected to be completed in September 2016 and will offer the expertise of UT Southwestern faculty specialty physicians at a multidisciplinary outpatient facility.

"My Dad would be pleased that the Moncrief Radiation Center that he created in Fort Worth years ago has now evolved into UT Southwestern's plan for a major clinic in Fort Worth to help take care of the medical needs of the citizens of Fort Worth and North Texas," said W.A. "Tex" Moncrief Jr., President of the William A. and Elizabeth B. Moncrief Foundation, which contributes to educational, health, civic, and cultural organizations. "UT Southwestern is known worldwide as a premier academic medical center that is fundamentally changing medicine through excellent clinical care, groundbreaking research, and the outstanding education it provides the next generation of physicians and caregivers."

Over the years, the Moncrief family has provided nearly $14 million from the William A. and Elizabeth B. Moncrief Foundation and from Tex Moncrief in direct support of UT Southwestern programs at its Dallas campus, as well as $75 million in funds given to the Moncrief Cancer Foundation in support of the UT Southwestern Moncrief Cancer Institute in Fort Worth.

In Dallas, the W.A. Monty & Tex Moncrief Radiation Oncology Building, adjacent to the Seay Biomedical Building at UT Southwestern, offers state-of-the-art radiation therapy and research equipment, and houses the Department of Radiation Oncology. The W. A. (Monty) Moncrief Distinguished Chair in Cholesterol and Arteriosclerosis Research is held by Nobel Laureate Dr. Michael Brown, who is also currently the Paul J. Thomas Professor of Molecular Genetics and Director of the Jonsson Center for Molecular Genetics at UT Southwestern.

"With this magnificent $25 million gift from Mr. Moncrief, UT Southwestern will be able to expand its presence in the Fort Worth area, providing advanced specialty care, access to clinical trials, and expertise that only an academic medical center can provide. This continues an era of growth for UT Southwestern," said Dr. Podolsky, who holds the Philip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science.

Fort Worth Mayor Betsy Price acknowledged the importance of the new Center. "One of my top priorities as Mayor has always been the health and well-being of our citizens. I'm delighted that UT Southwestern is expanding in Fort Worth, bringing even greater depth and dimension to the medical services available here," she said. "The Moncrief family is much more than a benefactor to this city. They have truly changed the landscape."

Tarrant County Judge Glen Whitley noted the expansion will benefit residents throughout Tarrant County and beyond. "UT Southwestern is a valuable partner in helping to ensure that residents from across the county and surrounding regions have access to the capabilities of this extraordinary academic medical center. Because of UT Southwestern's commitment, our residents benefit from top-tier care and the most advanced medical innovations."

New Campus to Provide Diverse Collection of Services

The campus will encompass the newly acquired property and the facility to be built there and the Moncrief Cancer Institute, located on a nearby 3.4-acre site at 400 W. Magnolia Ave. The latter Moncrief Cancer Institute supports North Texas cancer survivors, especially medically underserved adults, by focusing on prevention, research, and survivorship programs. The facility offers services that include genetic counseling, mammography screening, nutritional counseling, and healthy cooking classes. A telemedicine unit also allows the staff to provide testing and risk assessment to patients in surrounding and outlying counties. 

Dee J. Kelly, Sr., founding partner of Kelly Hart & Hallman LLP, who serves on the board of directors of the Moncrief Cancer Foundation, noted, "This fulfills a lifelong effort by Tex to honor his father by enabling UT Southwestern Medical Center to construct and operate a clinic in Fort Worth that will provide medical services that are innovative and unique, and will directly benefit the citizens of our community. This new outpatient facility builds upon and works closely with UT Southwestern's Moncrief Cancer Institute to offer additional and complementary clinical services."

In May, UT Southwestern opened facilities within the Moncrief Cancer Institute to provide easy access to the clinical expertise and services of the Harold C. Simmons Comprehensive Cancer Center for residents of Tarrant and 10 surrounding counties. This facility includes exam space, state-of-the-art imaging capabilities, on-site lab and pharmacy services, and 14 all-private infusion rooms for chemotherapy – which was a first for Fort Worth.

Secure telemedicine directly links to the Simmons Cancer Center in Dallas, allowing convenient access to consultations and secured access to electronic medical records, as well as extending the reach of oncologists, surgeons, and bone marrow transplant specialists at UT Southwestern's William P. Clements Jr. University Hospital and radiation oncologists at the W.A. Monty & Tex Moncrief Radiation Oncology Building.

In February 2015, the Moncrief Cancer Institute and Simmons Cancer Center debuted the Mobile Cancer Survivor Clinic – a custom-designed, $1.1 million, fully equipped 18-wheeler that can deliver follow-up and screening services to cancer survivors in their communities. The traveling clinic serves Tarrant, Parker, Wise, Hood, Erath, Somervell, Johnson, Ellis, and Navarro counties – a region where 55 percent of the population is considered medically underserved and where one-third of cancer survivors are considered at risk of failing to adhere to essential follow-up care due to the lack of facilities, lack of transportation, and other factors. The bilingual Mobile Cancer Survivor Clinic offers 3-D mammography, colon cancer screenings, private exam rooms, exercise facilities for one-on-one training, and high-speed telemedicine links to cancer experts and counseling services at UT Southwestern.

About W.A. "Monty" Moncrief

Mr. W.A. "Monty" Moncrief was one of Texas' legendary wildcatters. In 1931, he drilled one of the first wells in the East Texas oil field and made a major discovery extending the field. The Lathrop well came in at 18,000 barrels a day. The market was flooded with East Texas oil. Moncrief and his partners decided to sell their East Texas interest for $2.5 million. It later sold for over $37 million to Standard Oil Company. Mr. Moncrief then used the funds from the sale of his East Texas property to discover other major fields in West Texas, Florida and Louisiana.

About W.A. "Tex" Moncrief, Jr.

W.A. "Tex" Moncrief Jr. was born in 1920 in Fort Worth, and later graduated from the University of Texas in 1942 with a degree in petroleum engineering. After working as an engineer in the East Texas oil fields, he received a commission in the U.S. Naval Reserve and was trained at Harvard as a communications officer before serving in the Pacific.

After the war, he returned to Fort Worth and went into the oil business with his father. It was Tex Moncrief who made huge discoveries of natural gas in Wyoming, as well as major discoveries on the Gulf coast, in Texas and Louisiana.

Mr. Tex Moncrief has also been a huge supporter of athletics at the University of Texas and Texas Christian University, where the field is named after him and his father. Tex served on the Board of Regents from 1987 to 1993 and was named to the Texas Philanthropy Hall of Fame in 2001 and was honored as a Distinguished Alumnus by the University of Texas Exes in 2008.

About UT Southwestern Medical Center

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution's faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. The faculty of more than 2,700 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to about 92,000 hospitalized patients and oversee approximately 2.1 million outpatient visits a year.

Pennsylvania Department of Drug and Alcohol Programs Launches Facebook and Twitter Pages

The Department of Drug and Alcohol Programs (DDAP) today officially launched its Facebook and Twitter pages to provide better outreach to Pennsylvanians about substance use disorder and reach more individuals who need help finding services for substance use disorder.

"By launching these social media sites, we are working to provide a resource that will help address the epidemic of addiction in Pennsylvania," said DDAP Secretary Gary Tennis. "It is important for our department to help break down the stigma which surrounds addiction, by creating a platform where people can share stories about the importance of treatment services, and to provide an outlet to reach individuals or their loved ones who are struggling with substance use disorders."

Intrexon Prices Public Offering of Common Stock

Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has priced its previously announced underwritten public offering of common stock consisting of 4,878,049 shares at a public offering price of $41.00 per share. Gross proceeds to Intrexon from this offering are expected to be approximately $200 million and Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as for strategic acquisitions or investments.

Intrexon Corporation logo

Intrexon has granted the underwriters a 30-day option to purchase up to an additional 731,707 shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intrexon. The offering is expected to close on August 26, 2015, subject to customary closing conditions. JMP Securities LLC is acting as sole book-running manager and Stifel is acting as lead manager for the offering. Griffin Securities and Wunderlich Securities are acting as co-managers for the offering.

The public offering is being made pursuant an automatic shelf registration statement on Form S-3ASR that was previously filed with the Securities and Exchange Commission (SEC). A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from JMP Securities LLC, 600 Montgomery Street, Suite 1100, San Francisco, California  94111 or by telephone: +1 (415) 835-8985.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet.  The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.  We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com. 

Trademarks

Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

DST Announces Completion Of WMSI Acquisition

DST Systems, Inc. (NYSE: DST), a global provider of strategically unified data management, business processing, and customer communication solutions, today announced it has completed the previously announced acquisition of retirement plan rollover specialist Wealth Management Systems Inc. (WMSI).

DST Systems, Inc.

New York-based WMSI, a leading provider of retirement plan rollover technology, content and communications, and practice management solutions to the financial services industry, is connected to recordkeepers servicing over 33 million participants and provides automatic rollover services to over 25,000 plan sponsors.

"I'm confident that recordkeepers, sponsors, asset managers, TPAs, and financial advisors working in the retirement space will benefit from the remarkable synergy between DST and WMSI," said Jude Metcalfe, president of DST Retirement Solutions. "Our combined resources, capabilities, and commitment promise to bring an unmatched opportunity for our clients to grow and retain retirement assets."

As part of the DST enterprise, WMSI's comprehensive suite of services and rollover solutions will come to market as part of DST Retirement Solutions, a leading provider of defined contribution technology, strategic advisory, and business processing solutions to the retirement industry.

About DST

DST Systems, Inc. is a leading provider of sophisticated information processing and servicing solutions to companies around the world. Through its global enterprise, DST delivers strategically unified transactions and business processing, data management, and customer communications solutions to the asset management, brokerage, retirement, and healthcare markets. Headquartered in Kansas City, MO, DST is a publicly-traded company on the New York Stock Exchange. For more information, visit www.dstsystems.com.

Media Contact:

Laura M. Parsons                              
DST Global Public Relations
816.843.9087      
mediarelations@dstsystems.com

C4 Imaging Awarded $1.3 Million NIH SBIR Phase II Grant

C4 Imaging LLC today announced it has been awarded a $1.32 Million Phase II Small Business Innovation Research ("SBIR") grant from the National Cancer Institute of the National Institutes of Health ("NIH").  Entitled "Multi-Modality MRI/CT Markers for Improved Assessment of Prostate Cancer," the Phase II SBIR award will help fund the development of an enhanced multi-modality imaging marker based on C4 Imaging's commercially available Sirius™ MRI Marker.

This is the second NIH SBIR award for C4 Imaging.  C4 Imaging has successfully demonstrated a MRI Marker approach for radioactive seed localization that addresses the need to improve treatment assessment for men who undergo prostate brachytherapy.  Sirius™ is FDA approved for implantation in prostate cancer patients being treated with radioactive seeds (brachytherapy).  Its function is based on the unique paramagnetic properties of C4 Imaging's proprietary C4 solution.  This core technology was awarded a US patent in September 2013, with additional patent protection for further applications awarded in September 2014.  An enhanced, multi-modality version of the device will allow clinicians to utilize multiple imaging modalities for optimal anatomical visualization to improve treatment planning and assessment across a range of diseases.

"This phase II SBIR award is a significant achievement for us," said Andrew Bright, President and CEO of C4 Imaging. "It provides over $1 Million to support the further development of our patented C4 technology.  With this award, we can now accelerate our plans to develop additional MRI focused products for cancer patients within a large and growing MRI market."

The Phase II SBIR award will support a detailed development program; including product design, validation and manufacture, along with pre-clinical and clinical testing that will be performed in collaboration with the University of Texas MD Anderson Cancer Center.

About C4 IMAGING
C4 Imaging LLC develops innovative medical devices that enable clinicians to personalize patient treatment through accurate, image-guided procedures.  The company's core proprietary technology, C4, has been developed as Sirius™ the first commercially available Positive-Signal MRI Marker.  Further information is available at www.c4imaging.com.  The research described in this news release will be supported by the National Cancer Institute of the National Institutes of Health under Award Number R44CA199905.  The content is solely the responsibility of C4 Imaging and does not necessarily represent the official views of the National Institutes of Health.

Berg Partnership With University of Miami to Tackle Heart Disease

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030. The collaboration will utilize artificial intelligence to unlock new methods to battle the disease as there is a critical unmet need for markers for early detection of cardiac dysfunction and heart failure, which the partnership is aiming to fulfill.

"Through this collaboration with Berg, which merges the applications of technology and medicine, we expect to uncover novel insights into diseased environments as we work to reduce and further eradicate conditions such as cardiac dysfunction and heart failure," said Pascal J. Goldschmidt, M.D., Dean of the University of Miami Leonard M. Miller School of Medicine and CEO of UHealth – the University of Miami Health System. "The University of Miami will continue to form unique industry-academia relationships with innovative companies like Berg as we both work for meaningful discoveries and improved patient outcomes."

The University of Miami will provide Berg access to valuable clinical tissue samples obtained with patients' consent from its Miller School of Medicine. This is the first time the University of Miami has given a private research company access to these samples. These key assets, rich in data given South Florida's diverse population, are comprised of healthy and diseased cohorts.

"Berg will utilize its artificial intelligence based Interrogative Biology™ platform to analyze the tissues in an effort to uncover novel biomarkers for the prevention of cardiac dysfunction and heart failure," said Rangaprasad Sarangarajan, Ph.D., Chief Scientific Officer and Co-Founder of Berg Biosystems. "This will enable stratification of patients based on disease onset and progression, and to facilitate timely clinical intervention to improve patient outcomes."

Berg's Interrogative Biology™ platform has previously produced clinical assets in cancer and metabolic diseases, as well as diagnostics assets and markers in diseases including prostate cancer.

"The platform has the ability to look at disease and drug induced toxicity to predict heart failure and dysfunction," said Niven R. Narain, Co-founder, President and Chief Technology Officer of Berg. "In partnership with the University of Miami's leading researchers and with access to their diverse tissue samples, we can make life-saving strives in the discovery process for one of the most debilitating diseases."

According to Narain, Berg's ongoing collaborative relationship with the University of Miami is due to the growing environment for biotechnology and innovation in Florida.

Berg, the namesake of Chairman and Co-founder, Carl E. Berg, together with Co-Founders, Mitch Gray, Managing Director and Niven R. Narain, is a leading precision medicine company merging biology with Bayesian AI to fundamentally understand patient populations as a foundation to creating the next generation of drugs and diagnostics. Berg harnesses the power of technology to allow the patient biology to inform the direction of patient care.

To learn more about Berg, please visit www.berghealth.com. To learn more about the University of Miami Leonard M. Miller School of Medicine, please visit www.med.miami.edu.

About Berg

Berg, is a biopharmaceutical company with divisions that include Analytics, Pharma, Biosystems and Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of preclinical assets in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemo-toxicity. Armed with the use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow. For additional information, please visit www.berghealth.com.

About the Berg Interrogative Biology™ Platform 

Berg's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.

Lafayette General Health to acquire Regional Medical Center of Acadiana

Lafayette General Health (LGH) announced that it will acquire Regional Medical Center of Acadiana (RMCA) located on the corner of W. Congress Street and Ambassador Caffery from HCA MidAmerica, a division of Hospital Corporation of America (HCA), based in Nashville, TN.

The deal is expected to be complete in the 4th quarter of 2015. Once complete, LGH will own, operate and manage RMCA as an extension of Lafayette General Medical Center. HCA MidAmerica will continue to operate Women’s & Children’s Hospital (WCH) and Lafayette Surgicare.

“Because of our success in building a system of local, community-based, hospitals throughout Acadiana, our main tertiary referral facility, LGMC, has reached its capacity for more patients,” stated LGH President David L. Callecod, FACHE. “Acquiring RMCA will allow us to quickly increase our capacity to treat more patients in Lafayette, and give us more time to plan for greater tertiary service expansion at our Oil Center location after we become the region’s official emergency trauma center later this year.”

Under LGH, the RMCA facility will be renamed “Lafayette General Southwest.” It is licensed for 128 beds.

Under the terms of the agreement, RMCA staff will be extended employment opportunities within the LGH system following an application and pre-employment process.

Molecular diagnostic firm Myriad Genetics partners with Positive Bioscience

US-based molecular diagnostic firm Myriad Genetics has partnered with Positive Bioscience to bring molecular genomic testing in India for the treatment of cancer.

These tests will help screen for cancer risks and enable families of cancer patients to take various preventive measures. All testing will be carried out at Myriad's labs in USA and Germany, the companies said in a statement.

The companies however did not share the financial details of the partnership.

"Indian patients can now access tests such as BRACAnalysis to identify the risk of developing breast and ovarian cancer, colaris for hereditary colorectal cancer and myRisk test to assess the risk of developing eight cancers," Myriad Genetics International Operations Executive Vice-President Gary King said.

He added, "Our prognostic tests such as EndoPredict for breast cancer and Prolaris for prostate cancer will help to avoid both the over-treatment and under-treatment of patients and personalise patient care while reducing the economic burden of treatment."

Positive Bioscience CEO Samarth Jain said, "These tests will help patients by providing insights into potential healthcare challenges they may encounter and improve the quality of their lives."

Through this partnership, Positive Bioscience aims to reach millions of people in the country who are at higher risk of cancer and improve their quality of life, he added.

Translate »